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SUMMARY
SETTING—Multidrug-resistant tuberculosis (MDR-TB) treatment facility, Orel Oblast, Russian 
Federation.
OBJECTIVES—To determine factors associated with poor outcome and to document status of 
patients after recording of TB outcomes.
DESIGN—Retrospective review of prospective single cohort.
RESULTS—Among 192 patients, factors significantly associated with poor outcome in 
multivariate analysis include three or more treatment interruptions during the intensive phase of 
therapy and alcohol or drug addiction (adjusted OR [aOR] 2.1, 95%CI 1.0–4.3 and aOR 1.9, 
95%CI 1.0–3.7). Previous treatment was associated with poor outcome, but only among smear-
positive patients (aOR 3.1, 95%CI 1.3–7.3). Ten patients (5%) developed extensively drug-
resistant TB (XDR-TB) during treatment; of 115 patients with at least 6 months of follow-up data 
after outcomes were recorded, 13 (11%) developed XDR-TB.
CONCLUSION—Interventions focused on supporting patient adherence during the intensive 
phase of treatment; the management of drug and alcohol addiction should be developed and 
studied. A substantial proportion of patients developed XDR-TB during and after treatment. 
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Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB), defined as TB caused 
by Mycobacterium tuberculosis strains resistant to both isoniazid (INH) and rifampin 
(RMP), are significantly worse than for drug-susceptible TB, but have varied widely.1–4 
Moreover, patients documented as having a good outcome do not always do well over 
time.5–8 However, few reports have documented longer term follow-up of patients 
uniformly treated with second-line agents. Extensively drug-resistant TB (XDR-TB), 
defined as MDR-TB that is additionally resistant to a fluoroquinolone and an injectable 
second-line drug (SLD), is even more difficult to treat than MDR-TB;9–13 however, 
relatively little has been documented about the risks of developing XDR-TB during and after 
the treatment of MDR-TB.14
Political change and economic difficulties in Russia in the 1990s contributed to difficulties 
obtaining medications, which increased the incidence of MDR-TB.15 By 2000, the 
prevalence of MDR-TB among newly treated patients in some oblasts exceeded 9%.16 
Treatment success, and risk factors associated with outcome, among patients in MDR-TB 
treatment programs in countries of the former Soviet Union have varied.4,9,17,18 A better 
appreciation of these differences in treatment outcome may help elucidate reasons for 
treatment success or failure, and guide programmatic policy.
The Orel Oblast DOTS-Plus Tuberculosis Treatment Project was one of the first Green 
Light Committee (GLC) approved programs in the Russian Federation specifically designed 
to treat MDR-TB with individualized regimens. The first cohort began enrollment in 2002, 
and the program has been active since.
The purpose of this analysis was to investigate factors associated with poor treatment 
outcome in a cohort of MDR-TB cases enrolled in a DOTS-Plus project in Orel Oblast, 
Russia, and to describe cases with progression to XDR-TB during or after treatment.
STUDY POPULATION AND METHODS
Study setting
The DOTS-Plus program in Orel is a collaboration between the Central Tuberculosis 
Research Institute (CTRI) of the Russian Academy of Medical Sciences, the US Centers for 
Disease Control and Prevention (CDC), the World Health Organization (WHO) office in 
Moscow, and the Orel Oblast Health Department and TB Dispensary. Patients in this 
analysis were hospitalized at a central reference hospital in Orel City, generally for the 
duration of the intensive phase of treatment; thereafter, treatment was continued at an in-
patient or out-patient facility close to where the patient resided. Sputum smear microscopy 
was performed at TB clinics and dispensaries in each of the oblast’s raions (or districts), and 
cultures were performed at culture laboratories in the most populous raions. Drug 
susceptibility testing (DST) was performed for all drugs at the central TB laboratory at the 
Oblast TB Dispensary. External quality assurance and confirmatory testing were performed 
at CTRI and at the CDC TB laboratory in Atlanta.
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Patients are referred to the treatment program from across the oblast. Between 2002 and 
2005, 200 patients were enrolled into the first DOTS-Plus treatment program, composing the 
first treatment cohort. Many patients had received anti-tuberculosis treatment with available 
medications prior to enrollment.
For review of treatment outcomes, we included all patients who demonstrated resistance to 
at least RMP and INH. Patients were documented as prisoners if they were incarcerated at 
the time of enrollment, and as excessively using alcohol or drugs based on the determination 
of the clinician.
Procedures
Sputum was scheduled for collection from all patients at enrollment and then monthly 
throughout treatment. Sputum was processed using the modified Petroff method and 
concentrated by centrifugation at 3000× g. Smears were examined under regular light 
microscopy, and sediment was cultured on Löwenstein-Jensen (LJ) medium. Culture isolates 
were sent for DST using the absolute concentration method on LJ medium.
Initial DST was performed against INH, RMP, ethambutol (EMB) and streptomycin. 
Isolates resistant to INH and RMP were also tested for susceptibility to kanamycin (KM), 
capreomycin (CPM), ofloxacin (OFX), para-aminosalicylic acid, cycloserine (CS) and 
ethionamide.
Treatment regimens were based on the most recent DST prior to enrollment, and included 
pyrazinamide and any other first-line agents to which the organism was susceptible, a 
fluoroquinolone, an injectable agent, CS and prothionamide. Regimens were modified 
according to subsequent DST. All drugs were procured through the GLC.
Patients were actively followed during treatment, and default tracing using the local TB 
coordinators was used to locate and return patients to treatment. After outcomes were 
reported, patients were followed for relapse, but fewer resources were available for tracing, 
and follow-up data for those who relocated or died were often not documented.
Data collection and analysis
We abstracted clinical data from treatment forms in medical records and laboratory data 
from laboratory databases. We defined a clinically relevant treatment interruption as 
discontinuation of all prescribed drugs for a period of ≥4 days. Patient registration and 
treatment outcome definitions were those recommended by the WHO in 2008,19 with the 
exception that cure was documented on the basis of at least three (and not five) negative 
cultures in the final 12 months of treatment, with no cultures positive; failure was defined as 
any culture positive in the last 12 months of treatment. We further defined poor outcome as 
death from any cause, treatment failure or default; we defined favorable outcome as cure or 
treatment completion.
We calculated the risk of poor outcome associated with various factors, excluding from the 
analysis those who transferred out. We conducted a separate analysis to determine 
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associations with default, comparing the risk of default to other outcomes among patients 
who were cured, completed treatment or failed treatment. In addition, we performed 
descriptive analyses of the patients who developed XDR-TB either during or after treatment.
Comparative analyses were conducted using the t-test and Wilcoxon rank-sum test for 
continuous data, and Pearson’s χ2 or Fisher’s exact test for categorical data, where 
appropriate. A predictive multivariate analysis was conducted using logistic regression to 
obtain adjusted odds ratios (ORs). We used a cut-off of P ≤ 0.25 in univariate analysis to 
include variables in the original multivariate model. Variables were assessed for collinearity 
and effect modification. Using backward elimination, we developed a final model by 
retaining variables that had P ≤ 0.3, and stratified results by variables that exhibited effect 
modification. All data were analyzed with SAS version 9.2 (SAS Institute Inc, Cary, NC, 
USA).
Ethical considerations
This project was reviewed by the US CDC and approved as evaluation of a public health 
surveillance program; this does not require human subjects review or informed consent.
RESULTS
The characteristics of the 200 patients enrolled in the DOTS-Plus program are displayed in 
Table 1. In total, 165 (85%) were male and the mean age was 42 years; 144 (72%) patients 
were previously treated for TB, 102 with second-line agents; 133 patients (67%) had isolates 
that exhibited resistance to EMB, including 30/54 (56%) new patients and 101/144 (70%) 
previously treated patients. Sixty-nine patients (35%) had isolates resistant to a second-line 
injectable agent, including 34 to KM alone, two to CPM alone and 33 to both agents. Two 
patients (1%), both previously treated, had initial isolates resistant to OFX; 198 patients had 
initial resistance to both INH and RMP and are included in subsequent analyses.
Among the 198 MDR-TB patients, cure was documented in 108 (55%) and 10 (5%) 
completed treatment; 18 (9%) patients died during treatment and treatment failed in 30 
(15%); 26 (13%) defaulted and 6 (3%) transferred out of the region. Treatment was stopped 
for six patients for >2 months; these patients were clinically monitored, resumed treatment 
and had a reported outcome. We analyzed their outcomes as reported.
Of the 30 patients in whom treatment failed, 29 underwent DST during DOTS-Plus. By the 
end of treatment, the proportion of patients with resistance to SLDs had increased 
considerably: 20/29 (69%) had TB resistant to either KM or CPM and 9/29 (31%) had 
fluoroquinolone-resistant TB (Figure).
Among those with favorable outcomes, the mean total treatment duration was 621 days 
(standard deviation [SD] 109), the mean intensive phase regimen was 242 days (SD 89) and 
the mean continuation phase regimen was 377 days (SD 71). The median number of 
treatment interruptions during the intensive phase was one (range 0–14), and the median 
number of treatment interruptions during the continuation phase was two (range 0–17).
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Among patients in whom treatment failed, the mean total treatment duration was 465 days 
(SD 128). The median number of treatment interruptions during the intensive phase was two 
(range 0–26) and the median number of treatment interruptions during the continuation 
phase was four (range 0–12).
Excluding patients who transferred out of the region, factors significantly associated with 
poor outcome in univariate analyses of the remaining 192 patients were previous treatment, 
bilateral disease on initial chest radiograph, positive sputum smear at enrollment, three or 
more treatment interruptions during the intensive phase of treatment and addiction to alcohol 
or illicit drugs (Table 2). In multivariate analysis, smear status at enrollment modified the 
effect of previous treatment on outcome; the stratified results of the final model with the 
interaction are presented in Table 2. The strongest association with default was alcohol or 
drug addiction (OR 2.28, 95%CI 0.99–5.33, adjusted OR [aOR] 2.12, 95%CI 0.90–5.03).
Ten patients (5%) developed XDR-TB during the course of treatment. Of these, 4 died, 
treatment failed in 4, 1 transferred out and 1 was reported as cured. Among the 115 
remaining patients for whom there were at least 6 months of follow-up culture data after the 
reported treatment outcome, an additional 13 (11%) developed XDR-TB. Of these, 10 (77%) 
used illicit drugs or alcohol excessively, 5 (38%) had defaulted during treatment, treatment 
had failed in 6 (46%) and 2 (15%) had been reported as cured (Table 3). Among 70 patients 
who had a favorable outcome and for whom there were at least 12 months of follow-up 
culture data after treatment outcome, 7 (10%) had a subsequent positive culture after 
treatment outcome was documented.
DISCUSSION
Our analysis suggests that previous treatment, smear positivity at initiation of MDR-TB 
treatment and treatment interruptions during the intensive phase were associated with poor 
outcome. Alcohol or drug addiction also appeared to be associated with both poor outcome, 
which included defaulting, as well as with defaulting alone, but these associations did not 
reach conventional statistical significance in our analysis.
Previous research has described factors associated with poor outcome in patients treated for 
MDR-TB in DOTS-Plus programs in countries of the former Soviet Union,17,18,20,21 and the 
outcomes for this cohort were similar to descriptions in other treatment cohorts.9,17,22 
Default, while arguably distinct from death or treatment failure, was included in our 
definition of poor outcome to allow for a more complete program evaluation, consistent with 
previous analyses.18,20,22 As this was the first cohort of DOTS-Plus patients in the region, it 
is likely that this group was more sick than subsequent cohorts, with longer durations of 
disease and higher rates of previous treatment with, and consequent resistance to, second-
line agents—both of which were associated with poor treatment outcome in univariate 
analysis. In this cohort, over half of the patients had previously been treated with second-
line agents prior to enrollment, over a third of whom had resistance to a second-line agent. 
Equally worrying is the fact that 12/54 newly treated patients had resistance to second-line 
agents, suggesting transmission of resistant organisms in the community. Our data also 
suggest that previously treated patients with positive sputum smears at treatment initiation 
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may have a particularly high association with poor outcomes, even after adjusting for initial 
resistance to an injectable agent, but the lack of precision limits our conclusions. These 
patients may harbor a higher burden of organisms or may be a population that is more 
heterogeneous and with variable drug susceptibility, and may require more deliberately 
aggressive therapy during the intensive phase of treatment.
Treatment interruptions and alcohol or drug addiction were identified risks for poor outcome 
that are potentially modifiable. A predictive rule to identify patients at risk for treatment 
interruption has been developed,23 and focused interventions to prevent interruptions should 
be developed and evaluated. Alcoholism and drug addiction are prevalent among patients 
with TB disease in Russia,24,25 and while not statistically significant, our analysis suggests 
association with both poor outcome and default. This has been previously documented in 
other Russian TB programs.18,22,26,27 Alcohol and drug addiction can be treated in the 
context of anti-tuberculosis treatment in many ways using pharmaceutical, behavioral and 
other interventions,28 and these interventions urgently need evaluation.
Our data demonstrate that 5% of MDR-TB patients in this cohort developed XDR-TB 
during the course of treatment, a proportion similar to that described in another review of 
outcomes in Russia.14 The number of patients who developed XDR-TB after completion of 
treatment is worrying. This concern is amplified by the fact that 13% of the patients in this 
cohort defaulted, and for many of them, outcomes and follow-up are not known. Given the 
potentially catastrophic consequence of XDR-TB transmission in a community,29 more 
detailed research into risk factors for increased resistance should be performed and 
interventions to lower default rates should be evaluated and implemented. The high 
recurrence among patients who were successfully treated and for whom follow-up data were 
available, raises concerns and questions about current definitions of treatment outcomes. 
Longer term and more complete follow-up of patients after treatment for MDR-TB is 
needed, and the use of genotyping to distinguish between re-infection and relapse may help 
better characterize these findings.
Our analysis has several limitations. First, this was a retrospective review with a limited 
number of participants, and we were unable to control for additional factors that may have 
confounded or modified our findings. Alcohol and drug addiction were identified by 
experienced clinicians, but the reliability of these determinations is not certain. The 
reliability and reproducibility of DST against SLDs is questionable, and our conclusions 
about DST may not be fully generalizable. The relatively high rate of patients with unknown 
outcomes may bias the association between these risk factors and outcome, and this limits 
the confidence of these findings. The limited follow-up data on patients from this cohort, 
and the significant proportion of patients who were lost to follow-up after outcomes were 
recorded, restricts the conclusions that can be drawn from these findings and introduces the 
possibility of bias. Finally, the precision of the findings and conclusions were limited by the 
relatively small size of this cohort. Data collection, however, was thorough and 
documentation on a wide variety of variables was available. We believe that in spite of these 
limitations, this analysis expands upon previous reports about MDR-TB treatment in this 
region and highlights areas where further research is needed to inform programmatic policy.
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Drug resistance among patients in whom treatment failed (n = 30). INH = isoniazid; RMP = 
rifampin; EMB = ethambutol; SM = streptomycin; KM = kanamycin; CPM = capreomycin; 
OFX = ofloxacin; THI = thioamide; CS = cycloserine.
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Table 1
Patient characteristics at enrollment in a DOTS-Plus treatment program (N = 200)
Patient characteristic n (%)*
Sex
 Male 165 (83)
 Female 35 (18)
Age, years [range] 42 [16–75]
Prison status at treatment initiation
 Prisoner 21 (11)
 Non-prisoner 179 (90)
Initial smear status†
 Positive 139 (70)
 Negative 61 (31)
Initial culture status†
 Positive 143 (72)
 Negative 57 (29)
Treatment category and resistance pattern at treatment initiation‡
 New patients without SLD resistance 42 (21)
 New patients with SLD resistance 12 (6)
 Previously treated with FLDs without SLD resistance 24 (12)
 Previously treated with FLDs with SLD resistance 18 (9)
 Previously treated with SLDs without SLD resistance 64 (32)
 Previously treated with SLDs with SLD resistance 38 (19)
 Undetermined 2 (1)
Excessive alcohol or drug use
 Yes 69 (35)
 No 131 (66)
Cavitary disease
 Yes 171 (86)
 No 28 (14)
 Missing 1 (1)
Bilateral disease
 Yes 126 (63)
 No 73 (37)
 Missing 1 (1)
HIV infection
 Yes 0
 No 198 (99)
 Missing 2 (1)
Mean time from MDR-TB diagnosis to treatment, days 446
*
Some frequencies may not add up to 100% due to rounding.
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†
Initial documented positive culture or smear result within 30 days after enrollment into DOTS-Plus; some patients were being treated in a 
nonstandardized fashion and were culture- or smear-negative at enrollment.
‡
Data from the first culture and DST obtained after enrollment, or, for those who were culture-negative at enrollment, from the most recent 
previous positive results.
SLD = second-line drug; FLD = first-line drug; HIV = human immunodeficiency virus; MDR-TB = multidrug-resistant tuberculosis; DST = drug 
susceptibility testing.
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Table 2
Associations with poor outcome among MDR-TB patients, excluding patients who transferred out (n = 192)
Patient characteristic
Poor outcome
n/N (%) OR (95%CI)
Univariate
P value aOR (95%CI)*
Previously treated† 59/137 (43) 2.33 (1.14–4.74) 0.02 Smear-positive at start: 2.75 (0.80–9.44)
Smear-negative at start: 0.49 (0.12–2.03)
New† 13/53 (25) Reference Smear-positive at start: 0.82 (0.20–3.33)
Smear-negative at start: Reference
Sputum status
 Sputum-positive at start 63/134 (47) 3.79 (1.81–7.94) <0.001 See above
 Sputum-negative at start 11/58 (19) Reference See above
Age, years
 ≥42 46/106 (43) 1.49 (0.89–2.87) 0.13 —
 <42 28/86 (33) Reference
Sex
 Male 64/159 (40) 1.55 (0.69–3.47) 0.29 —
 Female 10/33 (30) Reference
Bilateral disease‡
 Bilateral 54/122 (44) 1.95 (1.04–3.66) 0.04 —
 Unilateral 20/69 (29) Reference
Cavitary disease‡
 Yes 67/165 (41) 1.86 (0.74–4.66) 0.18 —
 No 7/26 (27) Reference
Initial resistance to
 FLD and an injectable agent 30/65 (46) 1.62 (0.88–2.97) 0.12 1.67 (0.85–3.29)
 FLD only 44/127 (35) Reference Reference
Time of enrollment
 Before 2004 39/104 (38) 0.91 (0.51–1.63) 0.75 —
 In or after 2004 35/88 (40) Reference
Continuation phase
 In-patient 4/16 (25) Reference 0.25 —
 Out-patient 70/176 (40) 1.98 (0.61–6.39)
Time from MDR-TB to treatment
 <446 days 53/141 (38) 0.86 (0.45–1.65) 0.65 —
 ≥446 days 21/51 (41) Reference
Incarceration
 Yes 8/19 (42) 1.18 (0.45–3.08) 0.73 —
 No 66/173 (38) Reference
Treatment interruptions during intensive phase
 ≥3 26/49 (53) 2.24 (1.16–4.33) 0.02 2.07 (1.001–4.27)
 <3 48/143 (34) Reference Reference
Alcohol or drug addiction
 Yes 35/68 (52) 2.31 (1.26–4.24) 0.007 1.95 (0.99–3.82)
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Patient characteristic
Poor outcome
n/N (%) OR (95%CI)
Univariate
P value aOR (95%CI)*
 No 39/124 (31) Reference Reference
Surgical treatment
 Yes 8/18 (44) 1.31 (0.49–3.48) 0.59 —
 No 66/174 (38) Reference
*
Smear status at enrollment modified the effect of previous treatment on outcome, and these aORs are stratified. The referent for the stratified 
aORs is new patient, smear-negative.
†
Two previously treated patients with unknown regimens were excluded.
‡
One patient with no radiology report was excluded.
MDR-TB = multidrug-resistant tuberculosis; aOR = adjusted odds ratio; CI = confidence interval; FLD = first-line drug.
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Table 3
Characteristics of patients who developed XDR-TB and patients who did not after ≥ 6 months of follow-up 
after outcomes were reported
Patients who developed 
XDR-TB during 
treatment (n = 10)
n (%)
Patients who developed 
XDR-TB after treatment 
(n = 13)
n (%)
Patients who did not 
develop XDR-TB after ≥6 
months of follow-up (n = 
102)
n (%)
Male 8 (80) 12 (92) 83 (81)
Prisoners 1 (10) 2 (15) 5 (5)
Alcohol or drug addiction 4 (40) 10 (77) 29 (28)
Patients treated with FLDs before MDR-TB 
treatment
1 (10) 1 (8) 22 (22)
Patients treated with SLDs before MDR-TB 
treatment
5 (50) 9 (69) 48 (47)
Outcome of DOTS-Plus program
 Died 4 (40) NA NA
 Defaulted or transferred out 1 (10) 5 (38) 16 (16)
 Failed 4 (40) 6 (46) 12 (12)
 Cured 1 (10) 2 (15) 69 (68)
 Completed treatment 0 0 5 (5)
XDR-TB = extensively drug-resistant tuberculosis; FLD = first-line drug; MDR-TB = multidrug-resistant tuberculosis; SLD = second-line drug; 
NA = not applicable.
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